Anzeige
Mehr »
Dienstag, 17.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
347 Leser
Artikel bewerten:
(1)

Sunwin International Neutraceuticals to Aggressively Pursue Opportunities in Europe After the European Commission's Recent Regulatory Approval of Stevia

QUFU, China, Nov. 15, 2011 /PRNewswire/ -- Sunwin International Neutraceuticals, Inc. (OTC.BB: SUWN), one of the top global providers of high quality Stevia extracts including Rebaudioside A 98, announced today that management intends to aggressively pursue opportunities in Europe after the European Commission's ("EC's")recent approval of Stevia for use in the food and beverage industry.

In May of 2011 Sunwin announced a collaboration with two major companies in the flavouring and sweetener industry, operating in Europe as well as many other parts of the globe, to introduce a wide range of all natural, low calorie and no calorie sweetening solutions that contain Sunwin Stevia'. The EC decision opens the door to a vast potential market for consumers seeking natural low calorie sweetening alternatives. Management intends to work aggressively to open distribution channels in the EU in the coming quarters to expand its Stevia sales.

The Stevia rebaundiana plant is used to produce zero-calorie steviol glycosides, which are up to 300 times sweeter than sucrose. This approval by the EC is a significant milestone for the Stevia industry. While the European Food Safety Authority (EFSA) gave a positive safety opinion on steviol glycosides in April 2010, in line with the Joint FAO/WHO Expert Committee on Food Additives (JECFA), which approves the use of steviol glycosides at 95% purity or above, suppliers of Stevia had to wait for formal EC approval of steviol glycosides before entering the market.

Commenting on the EC's decision, Chairman Laiwang Zhang stated, "We are extremely pleased that the EC has given the regulatory go ahead for Stevia to be used in the EU food and beverage industry. Europe represents a vast market and we intend to work aggressively to establish European distribution of our Stevia products and work with industry leaders to develop unique products to address the needs of today's consumer seeking healthy, all natural, low calorie sweeteners."

About Sunwin International Neutraceuticals, Inc.

Sunwin International Neutraceuticals, Inc. engages in the areas of essential traditional Chinese medicine and zero calorie natural sweeteners (Sunwin Stevia' Extracts). As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. For more info about Sunwin, please visit http://www.sunwininternational.com.

Contact:

Lillian Wong
U.S. Representative
954-363-7333
ir@sunwininternational.com

Sunwin International Neutraceuticals, Inc., is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intends," "plans," "believes" and "projects") may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our guidance and expectations regarding revenues, net income and earnings.

We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the fiscal year ended April 30, 2011.

SOURCE Sunwin International Neutraceuticals, Inc.

© 2011 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.